{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:59:35Z","timestamp":1790787575527,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lymphomas are characterized by elevated synthesis of inflammatory soluble mediators that could trigger the development of venous thromboembolism (VTE). However, data on the relationship between specific immune dysregulation and VTE occurrence in patients with lymphoma are scarce. Therefore, this study aimed to assess the association between inflammatory markers and the risk of VTE development in patients with lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lactate dehydrogenase (LDH), total protein (TP), and albumin were assessed in 706 patients with newly diagnosed or relapsed lymphoma. Data were collected for all VTE events, while the diagnosis of VTE was established objectively based on radiographic studies. ROC (receiver operating characteristic) curve analysis was performed to define the optimal cutoff values for predicting VTE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The majority of patients was diagnosed with aggressive non-Hodgkin lymphoma (58.8%) and had advanced stage disease (59.9%). Sixty-nine patients (9.8%) developed VTE. The NLR, PLR, ESR, CRP, and LDH were significantly higher in the patients with lymphoma with VTE, whereas the TP and albumin were significantly lower in those patients. Using the univariate regression analysis, the NLR, PLR, TP, albumin, LDH, and CRP were prognostic factors for VTE development. In the multivariate regression model, the NLR and CRP were independent prognostic factors for VTE development. ROC curve analysis demonstrated acceptable specificity and sensitivity of the parameters: NLR, PLR, and CRP for predicting VTE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inflammatory dysregulation plays an important role in VTE development in patients with lymphoma. Widely accessible, simple inflammatory parameters can classify patients with lymphoma at risk of VTE development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-022-00381-3","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T05:03:24Z","timestamp":1650344604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Vladimir","family":"Otasevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Mihaljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Milic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejana","family":"Stanisavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojin","family":"Vukovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Tomic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawed","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Antic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"issue":"2","key":"381_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","volume":"72","author":"M Mukai","year":"2018","unstructured":"Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72(2):89\u201393.","journal-title":"J Cardiol"},{"issue":"6","key":"381_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715\u201322.","journal-title":"JAMA"},{"key":"381_CR3","first-page":"632","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. JTH England. 2007;5:632\u20134.","journal-title":"JTH England"},{"issue":"2","key":"381_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","volume":"22","author":"E Donnellan","year":"2017","unstructured":"Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;22(2):199\u2013207.","journal-title":"Oncologist"},{"issue":"1","key":"381_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.thromres.2012.10.008","volume":"131","author":"G Gussoni","year":"2013","unstructured":"Gussoni G, Foglia E, Frasson S, Casartelli L, Campanini M, Bonfanti M, et al. Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients. Thromb Res. 2013;131(1):17\u201323.","journal-title":"Thromb Res"},{"issue":"10091","key":"381_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet (London, England). 2017;390(10091):298\u2013310.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"381_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jncics\/pky082","volume":"2","author":"SB Makgoeng","year":"2018","unstructured":"Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC, et al. Markers of immune activation and inflammation, and non-Hodgkin lymphoma: a Meta-analysis of prospective studies. JNCI Cancer Spectr. 2018;2(4):1\u201313.","journal-title":"JNCI Cancer Spectr"},{"key":"381_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-3-0348-0837-8_12","volume":"816","author":"A Carbone","year":"2014","unstructured":"Carbone A, Tripodo C, Carlo-Stella C, Santoro A, Gloghini A. The role of inflammation in lymphoma. Adv Exp Med Biol. 2014;816:315\u201333.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"381_CR9","doi-asserted-by":"publisher","first-page":"R198","DOI":"10.1186\/cc12892","volume":"17","author":"A Koch","year":"2013","unstructured":"Koch A, Meesters MI, Scheller B, Boer C, Zacharowski K. Systemic endotoxin activity correlates with clot formation: an observational study in patients with early systemic inflammation and sepsis. Crit Care. 2013;17(5):R198.","journal-title":"Crit Care"},{"issue":"6","key":"381_CR10","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s10753-013-9675-2","volume":"36","author":"A Ahsen","year":"2013","unstructured":"Ahsen A, Ulu MS, Yuksel S, Demir K, Uysal M, Erdogan M, et al. As a new inflammatory marker for familial Mediterranean fever: neutrophil-to-lymphocyte ratio. Inflammation. 2013;36(6):1357\u201362.","journal-title":"Inflammation"},{"issue":"24","key":"381_CR11","doi-asserted-by":"publisher","first-page":"e14834","DOI":"10.1097\/MD.0000000000014834","volume":"98","author":"C Kumarasamy","year":"2019","unstructured":"Kumarasamy C, Sabarimurugan S, Madurantakam RM, Lakhotiya K, Samiappan S, Baxi S, et al. Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer\u2014a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2019;98(24):e14834.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"381_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.amjcard.2008.05.006","volume":"102","author":"UU Tamhane","year":"2008","unstructured":"Tamhane UU, Aneja S, Montgomery D, Rogers E-K, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653\u20137.","journal-title":"Am J Cardiol"},{"issue":"6","key":"381_CR13","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"381_CR14","doi-asserted-by":"publisher","first-page":"e101119","DOI":"10.1371\/journal.pone.0101119","volume":"9","author":"X Zhou","year":"2014","unstructured":"Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One. 2014;9(6):e101119.","journal-title":"PLoS One"},{"key":"381_CR15","first-page":"4","volume":"37","author":"Q Wang","year":"2018","unstructured":"Wang Q, Ma J, Jiang ZML. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis. Int Angiol. 2018;37:4\u201311.","journal-title":"Int Angiol"},{"issue":"1","key":"381_CR16","doi-asserted-by":"publisher","first-page":"e23010","DOI":"10.1002\/jcla.23010","volume":"34","author":"R Farah","year":"2020","unstructured":"Farah R, Nseir W, Kagansky D, Khamisy-Farah R. The role of neutrophil-lymphocyte ratio, and mean platelet volume in detecting patients with acute venous thromboembolism. J Clin Lab Anal. 2020;34(1):e23010.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"381_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11239-017-1528-7","volume":"44","author":"E Vazquez-Garza","year":"2017","unstructured":"Vazquez-Garza E, Jerjes-Sanchez C, Navarrete A, Joya-Harrison J, Rodriguez D. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis. 2017;44(3):377\u201385.","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"381_CR18","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1161\/CIRCRESAHA.121.318225","volume":"128","author":"ME Colling","year":"2021","unstructured":"Colling ME, Tourdot BE, Kanthi Y. Inflammation, infection and venous thromboembolism. Circ Res. 2021;128(12):2017\u201336.","journal-title":"Circ Res"},{"key":"381_CR19","doi-asserted-by":"publisher","first-page":"102322","DOI":"10.1016\/j.ctrv.2021.102322","volume":"102","author":"AT Bauer","year":"2022","unstructured":"Bauer AT, Gorzelanny C, Gebhardt C, Pantel K, Schneider SW. Interplay between coagulation and inflammation in cancer: limitations and therapeutic opportunities. Cancer Treat Rev. 2022;102:102322.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"381_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","volume":"13","author":"B Engelmann","year":"2013","unstructured":"Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34\u201345.","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"381_CR21","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","volume":"115","author":"V Caruso","year":"2010","unstructured":"Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, de Gaetano G, Storti S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood. 2010;115(26):5322\u20138.","journal-title":"Blood"},{"issue":"Suppl","key":"381_CR22","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0049-3848(14)50004-7","volume":"133","author":"A Mahajan","year":"2014","unstructured":"Mahajan A, Wun T, Chew H, White RH. Lymphoma and venous thromboembolism: influence on mortality. Thromb Res. 2014;133(Suppl):S23\u20138.","journal-title":"Thromb Res"},{"issue":"1","key":"381_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.thromres.2011.09.022","volume":"130","author":"K Yokoyama","year":"2012","unstructured":"Yokoyama K, Murata M, Ikeda Y, Okamoto S. Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma. Thromb Res. 2012;130(1):7\u201311.","journal-title":"Thromb Res"},{"issue":"12","key":"381_CR24","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1080\/10428194.2016.1185782","volume":"57","author":"IH Borg","year":"2016","unstructured":"Borg IH, Bendtsen MD, Bogsted M, Madsen J, Severinsen MT. Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(12):2771\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"381_CR25","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/cncr.23062","volume":"110","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339\u201346.","journal-title":"Cancer"},{"issue":"10","key":"381_CR26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/ajh.24466","volume":"91","author":"D Antic","year":"2016","unstructured":"Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol. 2016;91(10):1014\u20139.","journal-title":"Am J Hematol"},{"issue":"8","key":"381_CR27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ajh.25837","volume":"95","author":"G Dharmavaram","year":"2020","unstructured":"Dharmavaram G, Cao S, Sundaram S, Ayyapan S, Boughan K, Gallogly M, et al. Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma \u2013 specific venous thrombosis prediction models. Am J Hematol. 2020;95(8):918\u201326.","journal-title":"Am J Hematol"},{"issue":"4","key":"381_CR28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/cancers11040564","volume":"11","author":"L Wu","year":"2019","unstructured":"Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in Cancer: going pro. Cancers (Basel). 2019;11(4):564.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"381_CR29","first-page":"449","volume":"114","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114(3):449\u201358.","journal-title":"Thromb Haemost"},{"key":"381_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.avsg.2018.01.059","volume":"49","author":"S Wang","year":"2018","unstructured":"Wang S, Liu H, Wang Q, Cheng Z, Sun S, Zhang Y, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are effective predictors of prognosis in patients with acute mesenteric arterial embolism and thrombosis. Ann Vasc Surg. 2018;49:115\u201322.","journal-title":"Ann Vasc Surg"},{"key":"381_CR31","first-page":"9651254","volume":"2018","author":"S Wang","year":"2018","unstructured":"Wang S, Ma Y, Sun L, Shi Y, Jiang S, Yu K, et al. Prognostic significance of pretreatment neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio in patients with diffuse large B-cell lymphoma. Biomed Res Int. 2018;2018:9651254.","journal-title":"Biomed Res Int"},{"issue":"30","key":"381_CR32","doi-asserted-by":"publisher","first-page":"e16180","DOI":"10.1097\/MD.0000000000016180","volume":"98","author":"SH Haydaroglu","year":"2019","unstructured":"Haydaroglu SH. Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts? Medicine (Baltimore). 2019;98(30):e16180.","journal-title":"Medicine (Baltimore)"},{"key":"381_CR33","first-page":"100173","volume":"12","author":"Y Azuma","year":"2019","unstructured":"Azuma Y, Nakaya A, Fujita S, Satake A, Nakanishi T, Tsubokura Y, et al. Neutrophil-to-lymphocyte ratio (NLR) fails to predict outcome of diffuse large B cell lymphoma. Leuk Res Rep. 2019;12:100173.","journal-title":"Leuk Res Rep"},{"issue":"5","key":"381_CR34","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/ijc.29076","volume":"136","author":"P Ferroni","year":"2015","unstructured":"Ferroni P, Riondino S, Formica V, Cereda V, Tosetto L, La Farina F, et al. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio. Int J Cancer. 2015;136(5):1234\u201340.","journal-title":"Int J Cancer"},{"issue":"5","key":"381_CR35","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1177\/1076029617733039","volume":"24","author":"A Artoni","year":"2018","unstructured":"Artoni A, Abbattista M, Bucciarelli P, Gianniello F, Scalambrino E, Pappalardo E, et al. Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as risk factors for venous thrombosis. Clin Appl Thromb Hemost. 2018;24(5):808\u201314.","journal-title":"Clin Appl Thromb Hemost"},{"key":"381_CR36","doi-asserted-by":"publisher","first-page":"677776","DOI":"10.3389\/fonc.2021.677776","volume":"11","author":"H Abdel-Razeq","year":"2021","unstructured":"Abdel-Razeq H, Ma\u2019koseh M, Abdel-Razeq R, Amarin R, Abufara A, Mansour R, et al. The application of the lymphoma international prognostic index to predict venous thromboembolic events in diffuse large B-cell lymphoma patients. Front Oncol. 2021;11:677776.","journal-title":"Front Oncol"},{"key":"381_CR37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.critrevonc.2016.01.007","volume":"99","author":"A Saghazadeh","year":"2016","unstructured":"Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. Crit Rev Oncol Hematol. 2016;99:272\u201385.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"36","key":"381_CR38","doi-asserted-by":"publisher","first-page":"15880","DOI":"10.1073\/pnas.1005743107","volume":"107","author":"TA Fuchs","year":"2010","unstructured":"Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DDJ, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"381_CR39","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.2174\/092986707781389664","volume":"14","author":"P Ferroni","year":"2007","unstructured":"Ferroni P, Santilli F, Guadagni F, Basili S, Davi G. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr Med Chem. 2007;14(20):2170\u201380.","journal-title":"Curr Med Chem"},{"issue":"2\u20133","key":"381_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-3083.2007.01984.x","volume":"66","author":"SP Ardoin","year":"2007","unstructured":"Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol. 2007;66(2\u20133):159\u201365.","journal-title":"Scand J Immunol"},{"key":"381_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.thromres.2018.08.005","volume":"170","author":"S Kapoor","year":"2018","unstructured":"Kapoor S, Opneja A, Nayak L. The role of neutrophils in thrombosis. Thromb Res. 2018;170:87\u201396.","journal-title":"Thromb Res"},{"issue":"1","key":"381_CR42","first-page":"742","volume":"24","author":"D Borgel","year":"2019","unstructured":"Borgel D, Bianchini E, Lasne D, Pascreau T, Saller F. Inflammation in deep vein thrombosis: a therapeutic target? Hematol (United Kingdom). 2019;24(1):742\u201350.","journal-title":"Hematol (United Kingdom)"},{"issue":"Supplement_1","key":"381_CR43","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1182\/blood-2019-129957","volume":"134","author":"D Antic","year":"2019","unstructured":"Antic D, Milic N, Bontekoe E, Hoppensteadt D, Djurasinovic V, Vukovic V, et al. Biomarkers of hemostatic dysregulation and inflammation in lymphoma: potential relevance to Thrombogenesis. Blood. 2019;134(Supplement_1):4945.","journal-title":"Blood"},{"issue":"3","key":"381_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2302\/kjm.2014-0017-RE","volume":"64","author":"K Yokoyama","year":"2015","unstructured":"Yokoyama K. Thrombosis in lymphoma patients and in myeloma patients. Keio J Med. 2015;64(3):37\u201343.","journal-title":"Keio J Med"},{"issue":"6","key":"381_CR45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.thromres.2010.08.017","volume":"126","author":"D Lekovic","year":"2010","unstructured":"Lekovic D, Miljic P, Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res. 2010;126(6):477\u201380.","journal-title":"Thromb Res"},{"issue":"6","key":"381_CR46","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/CCO.0b013e3283592331","volume":"24","author":"A Falanga","year":"2012","unstructured":"Falanga A, Marchetti M, Russo L. Venous thromboembolism in the hematologic malignancies. Curr Opin Oncol. 2012;24(6):702\u201310.","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"381_CR47","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/cncr.11623","volume":"98","author":"N Goldschmidt","year":"2003","unstructured":"Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer. 2003;98(6):1239\u201342.","journal-title":"Cancer"},{"key":"381_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","volume":"33","author":"N Kekre","year":"2019","unstructured":"Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 2019;33:24\u201332.","journal-title":"Blood Rev"},{"key":"381_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.thromres.2016.05.008","volume":"143","author":"KM Sanfilippo","year":"2016","unstructured":"Sanfilippo KM, Wang TF, Gage BF, Luo S, Riedell P, Carson KR. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thromb Res. 2016;143:86\u201390.","journal-title":"Thromb Res"},{"issue":"2","key":"381_CR50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.blre.2017.10.002","volume":"32","author":"D Antic","year":"2018","unstructured":"Antic D, Jelicic J, Vukovic V, Nikolovski S, Mihaljevic B. Venous thromboembolic events in lymphoma patients: actual relationships between epidemiology, mechanisms, clinical profile and treatment. Blood Rev. 2018;32(2):144\u201358.","journal-title":"Blood Rev"},{"issue":"6","key":"381_CR51","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.clml.2014.05.003","volume":"14","author":"R Colombo","year":"2014","unstructured":"Colombo R, Gallipoli P, Castelli R. Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk. 2014;14(6):441\u201350.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"381_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12959-019-0196-6","volume":"17","author":"B Brenner","year":"2019","unstructured":"Brenner B, Hull R, Arya R, Beyer-Westendorf J, Douketis J, Elalamy I, et al. Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. Thromb J. 2019;17(1):6.","journal-title":"Thromb J"},{"key":"381_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.thromres.2019.10.002","volume":"183","author":"JM Byun","year":"2019","unstructured":"Byun JM, Hong J, Yoon S-S, Koh Y, Ock C-Y, Kim TM, et al. Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy. Thromb Res. 2019;183:131\u20135.","journal-title":"Thromb Res"},{"issue":"3","key":"381_CR54","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1016\/j.thromres.2012.03.019","volume":"130","author":"LC Park","year":"2012","unstructured":"Park LC, Woo S, Kim S, Jeon H, Ko YH, Kim SJ, et al. Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population. Thromb Res. 2012;130(3):E6\u201312.","journal-title":"Thromb Res"},{"issue":"8","key":"381_CR55","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/annonc\/mdz168","volume":"30","author":"S Borchmann","year":"2019","unstructured":"Borchmann S, Muller H, Hude I, Fuchs M, Borchmann P, Engert A. Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin study group (GHSG) trials. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(8):1329\u201334.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"5","key":"381_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12051291","volume":"12","author":"S Hohaus","year":"2020","unstructured":"Hohaus S, Bartolomei F, Cuccaro A, Maiolo E, Alma E, D\u2019al\u00f2 F, et al. Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers (Basel). 2020;12(5):1\u201317.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"381_CR57","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12032-017-1065-4","volume":"35","author":"J Rupa-Matysek","year":"2017","unstructured":"Rupa-Matysek J, Gil L, Kazmierczak M, Baranska M, Komarnicki M. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana risk score. Med Oncol. 2017;35(1):5.","journal-title":"Med Oncol"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-022-00381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-022-00381-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-022-00381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T05:10:21Z","timestamp":1650431421000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-022-00381-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["381"],"URL":"https:\/\/doi.org\/10.1186\/s12959-022-00381-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1025522\/v1","asserted-by":"object"}]},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"27 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mentioned in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}